Share
27,739 Posts.
lightbulb Created with Sketch. 1789
clock Created with Sketch. 11/04/22
21:14
Share
Originally posted by showie
↑
The bid of Pfizers is not a shot across the bow. This had absolutely negotiated for a long time between both parties and brought to shareholders / accepted by BOD for a reason (to be made public & secure capital for covid trials) potentially even a conditional offer would have been made pre covid trail results.
Expand
I guess this wasn't Pfizer "decision" but the board wanted this as part of the R&D license deal???? If so, smart on them to cap the pps at 11c pending more license agreement for ResAppDx-EU. Chronic respiratory management for Asthma and COPD will also be a massive market for big pharmacy, hence why a subsidiary of J&J is doing a pilot for RSV.https://www.resapphealth.com.au/resapp-secures-contract-with-global-pharmaceutical-company/
